Serial interferon-gamma release assays after chemoprophylaxis in a tuberculosis outbreak cohort

Infection

Volumn 40, Issue 4, 2012, Pages 431-435

  Lee, S W ^a,b   Lee, S H ^c   Yim, J J ^d  

^a Armed Forces Capital Hospital   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Korean Institute of Tuberculosis   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

Author keywords

Interferon release assay; Latent tuberculosis infection; Tuberculosis

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; ISONIAZID; RIFAMPICIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; FEMALE; FOLLOW UP; HUMAN; INTERFERON GAMMA RELEASE ASSAY; MALE; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; THORAX RADIOGRAPHY; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; DISEASE OUTBREAKS; HUMANS; INTERFERON-GAMMA RELEASE TESTS; ISONIAZID; MALE; RIFAMPIN; TUBERCULOSIS; YOUNG ADULT;

EID: 84866731322     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-012-0265-2     Document Type: Article

References (27)

1. World Health Organization: Global tuberculosis control-epidemiology, strategy, financing. World Health Organization, Geneva; 2009.
2. Broekmans JF, Migliori GB, Rieder HL, Lees J, Ruutu P, Lod-denkemper R, Raviglione MC. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. E. Eur Respir J. 2002;19:765-75.
3. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146:340-54.
4. Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, Yim JJ. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA. 2005;293:2756-61.
5. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149:177-84.
6. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2008;177:1164-70.
7. Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A. Negative and positive predictive value of a whole-blood interferon-{gamma} release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med. 2011;183:88-95.
8. Kik SV, Franken WP, Mensen M, Cobelens FG, Kamphorst M, Arend SM, Erkens C, Gebhard A, Borgdorff MW, Verver S. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. Eur Respir J. 2010;35:1346-53.
9. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection-United States. MMWR Recomm Rep. 2010;59:1-25.
10. Carrara S, Vincenti D, Petrosillo N, Amicosante M, Girardi E, Goletti D. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis. 2004;38:754-6.
11. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2006;174:831-9.
12. Chee CB, KhinMar. KW, Gan SH, Barkham TM, Pushparani M, Wang YT. Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am J Respir Crit Care Med. 2007;175:282-7.
13. Dyrhol-Riise AM, Gran G, Wentzel-Larsen T, Blomberg B, Haanshuus CG, Morkve O. Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country. BMC Infect Dis. 2010;10:57.
14. Higuchi K, Harada N, Mori T. Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis. Respirology. 2008;13:468-72.
15. Higuchi K, Okada K, Harada N, Mori T. Effects of prophylaxis on QuantiFERON TB-2G responses among children. Kekkaku. 2008;83:603-9.
16. Lee SW, Oh DK, Lee SH, Kang HY, Lee CT, Yim JJ. Time interval to conversion of interferon-gamma release assay after exposure to tuberculosis. Eur Respir J. 2011;37:1447-52.
17. Control and prevention of tuberculosis in the United Kingdom: code of practice. Joint Tuberculosis Committee of the British Thoracic Society. Thorax 2000. 2000;55:887-901.
18. Lee SH, Lew WJ, Kim HJ, Lee HK, Lee YM, Cho CH, Lee EJ, Lee DY, Ryu SW, Oh SY et al.: Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak. Respir Med 2009.
19. Kobashi Y, Sugiu T, Ohue Y, Mouri K, Obase Y, Miyashita N, Oka M. Long-term follow-up of the QuantiFERON TB-2G test for active tuberculosis disease. Intern Med. 2008;47:1957-61.
20. Wilkinson KA, Kon OM, Newton SM, Meintjes G, Davidson RN, Pasvol G, Wilkinson RJ. Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. J Infect Dis. 2006;193:354-9.
21. Lee SW, Lee CT, Yim JJ. Serial interferon-gamma release assays during treatment of active tuberculosis in young adults. BMC Infect Dis. 2010;10:300.
22. Fernandez-Funez A. Paradoxical response during anti-tuberculosis treatment in immunocompetent patients. Med Clin. 2009;133:637-43.
23. Jurcevic S, Hills A, Pasvol G, Davidson RN, Ivanyi J, Wilkinson RJ. T cell responses to a mixture of Mycobacterium tuberculosis peptides with complementary HLA-DR binding profiles. Clin Exp Immunol. 1996;105:416-21.
24. Wilkinson RJ, Vordermeier HM, Wilkinson KA, Sjolund A, Moreno C, Pasvol G, Ivanyi J. Peptide-specific T cell response to Mycobacterium tuberculosis: clinical spectrum, compartmentali-zation, and effect of chemotherapy. J Infect Dis. 1998;178:760-8.
25. Shams H, Wizel B, Weis SE, Samten B, Barnes PF. Contribution of CD8 (+) T cells to gamma interferon production in human tuberculosis. Infect Immun. 2001;69:3497-501.
26. Garcia M, Vargas JA, Castejon R, Navas E, Durantez A. Flow-cytometric assessment of lymphocyte cytokine production in tuberculosis. Tuberculosis (Edinb). 2002;82:37-41.
27. van Zyl-Smit RN, Pai M, Peprah K, Meldau R, Kieck J, Juritz J, Badri M, Zumla A, Sechi LA, Bateman ED, et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med. 2009;180:49-58.